Clinical Trial Update: Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation [Phase 1]

View source ↗

Summary

Phase 1 study of MRTX1133 in KRAS G12D-mutant solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Adenocarcinoma

Drugs mentioned

• MRTX1133

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Solid Tumor, Advanced Solid Tumor | Phase 1 | Status: TERMINATED